CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new drug leads for type 2 diabetes, obesity, and immune diseases. It involves identifying protein interactions and designing drugs using advanced computational methods and yeast-based systems to validate potential therapies.
The Pharmaceutical sector is a mainstay of the European economy.
However, changing patterns of drug discovery and competition has greatly enhanced the need for a SME sector to produce new drug leads and targets to feed big Pharma pipelines.
This application addresses the need by coalescing partners involved in the identification/validation of new targets and in drug design, synthesis and discovery.
The focus is on type 2 diabetes, obesity and immune diseases which cause serious disability and re…
NATIONAL UNIVERSITY OF IRELAND MAYNOOTH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Zurich-Schlieren
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, Sheffield
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
